An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...

The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

Ataciguat, a new drug being studied for aortic valve stenosis, shows promise in slowing disease progression and reducing the ...

Serious heart problems kept one local senior from dancing with his wife. But thanks to a life-saving procedure at White ...

Sanofi's experimental drug ataciguat has shown promise in reducing the progression of aortic valve stenosis in clinical trials, potentially delaying the need for surgical valve replacement. With ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers at Mayo Clinic are exploring the use of a new drug called ...

Discover how recent advancements in cardiovascular medicine, including TAVI and TEER, are revolutionizing heart disease ...

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

The Society for Cardiovascular Angiography & Interventions (SCAI) has published an expert consensus statement that provides ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage ...